Worldwide PAH Marketplace Analysed by Daedal Research in Topical Study Now Available at MarketPublishers.com
26 Aug 2015 • by Natalie Aster
LONDON – During the next five years, the global pulmonary arterial hypertension (PAH) market revenues are forecast to remain stable owing to the patent expiration and launch of novel drugs. To date, there are new treatments available that go beyond symptom management to treat the ultimate cause of the disease. With advances in the standard of care, patients are capable of maintaining active lifestyles with a lower risk of serious cardiac events pertaining to PAH.
In 2001, Actelion’s Tracleer was approved by U.S. FDA for the treatment of patients with PAH. This key revenue generating drug in the global PAH market is anticipated to go off patent by the end of 2015.
In spite of a hike in spending per member per year during 2013-2014, trend for medications utilised to treat pulmonary hypertension is set to be weak again in 2015, mainly due to the market saturation of generic Sildenafil. The world PAH market is forecast to generate the highest sales in 2017 owing to oncoming release of the PAH drug Uptravi (Selexipag) in 2016, which is anticipated to propel the growth of the overall market through to 2019. Popularity of polytherapies will also likely drive the sector’s growth in the offing. Actelion Ltd., and SteadyMed Ltd. and United Therapeutics Ltd. are the leading players in the market space.
Topical research report “Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)” prepared by Daedal Research offers a comprehensive analysis of the world PAH market. The study evaluates the market size and offers forecasts in terms of value for the global PAH market for the period 2010-2019, with 2014 considered as the base year. The report provides detailed analysis of the global PAH market size and growth by type for the period 2010-2014. The market is segmented based on drug mechanism and various dosage forms. An in-depth analysis of the sales of individual PAH drugs is also available. The research publication profiles the top market players, covering company overview, financial overview, latest developments, business strategies adopted by the leaders in the market.
Global Pulmonary Arterial Hypertension (PAH) Market: Trends & Opportunities (2015-2019)
Published: July, 2015
Price: US$ 800.00
More reports by the publisher can be found at Daedal research page.